PAKMAG

Pakmag is an Australian biotechnology company focused on the development of novel small molecule inhibitors targeting p21-activated kinase 1 (PAK1). PAK1 is a key signaling protein that is frequently overexpressed in various cancers and is associated with tumor growth, survival, and resistance to therapy. The company's research, originating from the University of Sydney, aims to develop potent and selective PAK1 inhibitors for the treatment of aggressive malignancies, including pancreatic, breast, and ovarian cancers. Pakmag is currently advancing its lead candidates through pre-clinical development to address significant unmet needs in oncology.